# uniQure N.V. (QURE) — capital_raise/public_offering [announced]
Source: SEC API (secapi.ai) · situation sit_e67a8d52fdcd6b99abbb · retrieved 2026-08-11T15:49:17.905Z

## Overview
uniQure N.V. is a gene therapy company advancing transformative therapies for patients with severe medical needs, including programs for Huntington's disease, refractory mesial temporal lobe epilepsy, and Fabry disease.

uniQure N.V. closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 per share in June 2026, generating gross proceeds of $259 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The company stated that these resources, combined with its existing cash position of $810.3 million as of June 30, 2026, are expected to be sufficient to fund projected operating expenses into 2030.

## Terms
- Counterparty: Underwriters · Deal value: $259.0M · Consideration: cash · Price/share: $45.5

## Key dates
- Announced 2026-07-29

## Timeline
- 2026-07-29 · 8-K (0001104659-26-087808): 8-K - uniQure N.V. — *uniQure N.V. is a gene therapy company advancing transformative therapies for patients with severe medical needs, including programs for Huntington's disease, refractory mesial temporal lobe epilepsy, and Fabry disease.* uniQure N.V. closed an upsized underwritten public offering of 5,686,813 ordinary shares at $45.50 per share in June 2026, generating gross proceeds of $259 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The company stated that these resources, combined with its existing cash position of $810.3 million as of June 30, 2026, are expected to be sufficient to fund projected operating expenses into 2030.
  https://www.sec.gov/Archives/edgar/data/1590560/0001104659-26-087808.txt

## Citations
- 0001104659-26-087808 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926087808